Thus, the use of heteronemin in a synergistic strategy with Ara-C by inhibiting the farnesylated Ras-MAPK-NF-κB/AP-1 axis has been suggested to sensitize AML cells to Ara-C [66] (Figure 3b(vi)). Here, NFKB1 is linked to acute myeloid leukemia.